MedPath

Establishment and Clinical Transformation of ADC Drug Efficacy Evaluation System for Breast Cancer Based on Molecular Imaging

Not Applicable
Not yet recruiting
Conditions
Breast Cancer
Interventions
Registration Number
NCT06715020
Lead Sponsor
Peking University Cancer Hospital & Institute
Brief Summary

The objective of the study is to construct a noninvasive approach 68Ga-TTP PET/CT to detect the TROP2 expression of tumor lesions in patients with breast tumors and evaluate the efficacy of ADC drug therapy.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
60
Inclusion Criteria
  1. Age 18-75 years old, male or female, ECOG score 0 or 1 points (see the table in Annex 2 for the score table);
  2. Blood routine and liver and kidney function meet the following criteria: Blood routine: WBC ≥ 4.0×109 L or neutrophil ≥1.5×109 /L, PLT ≥ 100×109/L, Hb≥ 90 g/L; PT or APTT ≤ 1.5 ULN; Liver and kidney function: T-Bil ≤ 1.5×ULT(upper limit of normal), ALT and AST≤ 2.5 ULN or ≤ 5×ULT(subjects with liver metastasis), ALP ≤ 2.5 ULN(ALP ≤ 4.5 ULN if there is bone metastasis or liver metastasis); BUN ≤ 1.5×ULT, SCr ≤ 1.5×ULT;
  3. Patients with confirmed or suspected breast cancer;
  4. Expected survival ≥12 weeks;
  5. Good follow-up compliance;
  6. Women of childbearing age (15 to 49 years old) must undergo a pregnancy test within 7 days before the start of the test and the result is negative; Fertile men and women must consent to the use of effective contraception to ensure pregnancy during the study period and within 3 months of the examination;
  7. Subject patients can fully understand and voluntarily participate in this experiment, and sign informed consent.
Read More
Exclusion Criteria
  1. Severe abnormal liver and kidney function;
  2. Pregnant, pregnant and lactating women;
  3. Can not lie flat for half an hour;
  4. Unable to obtain informed consent;
  5. Suffering from claustrophobia or other mental illness;
  6. People who are known to be allergic to the investigational drug or its excipients in the investigational therapy;
  7. Other conditions deemed unsuitable for participation in the trial by the investigator.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
68Ga-TTP18F-FDGAll study participants will be allocated to this arm (single-arm study).Study participants will undergo 68Ga-TTP PET scans
Primary Outcome Measures
NameTimeMethod
Standardized uptake value(SUV)2 years

The uptake of the tracer (68Ga-TTP) in solid tumor lesions or suspected tumor lesions by measuring SUV on PET/CT.

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath